

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE 500ml and 750 ml  
bottles**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Addimag 160 mg/ml + 84 mg/ml solution for infusion

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains:

Calcium gluconate monohydrate      160 mg (equivalent to 14.3 mg or 0.36 mmol calcium)

Magnesium chloride hexahydrate      84 mg (equivalent to 10.0 mg or 0.41 mmol magnesium)

**3. PACKAGE SIZE**

500 ml

750 ml

**4. TARGET SPECIES**

Cattle



**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Slow intravenous use

**7. WITHDRAWAL PERIODS**

Withdrawal period:

Meat and offal:      Zero days

Milk:      Zero hours

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached, use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Do not refrigerate or freeze.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Alfasan Nederland B.V.

**14. MARKETING AUTHORISATION NUMBERS**

Vm 36408/4003

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

**PACKAGE LEAFLET**

**1. Name of the veterinary medicinal product**

Addimag 160 mg/ml + 84 mg/ml solution for infusion for cattle

**2. Composition**

Each ml contains:

**Active substance:**

Calcium gluconate monohydrate	160 mg (equivalent to 14.3 mg or 0.36 mmol calcium)
Magnesium chloride hexahydrate	84 mg (equivalent to 10.0 mg or 0.41 mmol magnesium)

**Excipients:**

Boric acid (E284)	32 mg
Glucose monohydrate	110 mg

Clear, yellow to brown solution.

**3. Target species**

Cattle



**4. Indications for use**

For the treatment of clinical hypomagnesaemia (grass tetany) accompanied by deficiency of calcium and for the treatment of clinical hypocalcaemia (milk fever) complicated by deficiency of magnesium

**5. Contraindications**

Do not use in cases of hypercalcaemia and hypermagnesemia.  
Do not use in cases of calcinosis in cattle.  
Do not use following administration of high doses of vitamin D3.  
Do not use in cases of chronic kidney insufficiency or in cases of circulatory or cardiac disorders.  
Do not use in cases of septicaemic processes in the course of acute mastitis in cattle.

**6. Special warnings**

Special precautions for use in animals:

The medicinal product must be administered slowly, at body temperature.

During infusion, the heart rate, rhythm and circulation must be monitored. In case of symptoms of overdosing (bradycardia cardiac arrhythmia, fall in blood pressure, agitation), the infusion should be stopped immediately.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Not applicable

Pregnancy and Lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

Calcium increases the efficacy of cardiac glycosides and arrhythmias may occur if these drugs are given together.

Calcium amplifies the cardiac effects of  $\beta$ -adrenergic drugs and methylxanthines.

Glucocorticoids increase the renal excretion of calcium by way of vitamin D antagonism.

Do not administer inorganic phosphate solutions simultaneously or shortly after the infusion.

Overdose (symptoms, emergency procedures, antidotes):

When the intravenous administration is performed too rapidly, hypercalcaemia and/or hypermagnesaemia with cardiotoxic symptoms such as initial bradycardia with subsequent tachycardia, cardiac arrhythmia and in severe cases ventricular fibrillation with cardiac arrest may occur.

Additional symptoms of hypercalcaemia are: motor weakness, muscle tremors, increased excitability, agitation, sweating, polyuria, fall in blood pressure, depression and coma.

Symptoms of hypercalcaemia may persist 6 – 10 hours after the infusion and must not be incorrectly diagnosed as symptoms of hypocalcaemia.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## 7. Adverse events

Cattle:

Undetermined frequency (cannot be estimated from available data)	Hypercalcaemia <sup>1,2</sup> ; increased respiratory rate <sup>1,2</sup> ; bradycardia <sup>1,2</sup> , tachycardia <sup>1,2,3</sup> , arrhythmia <sup>1,2,4</sup> ; muscle tremor <sup>1,2</sup> ; increased salivation <sup>1,2</sup> .
--	--

<sup>1</sup> too rapid administration of the product may cause these effects.

<sup>2</sup> transient.

<sup>3</sup> increase in heart rate following initial bradycardia may indicate that overdosing has occurred. In this case the administration should be stopped immediately.

<sup>4</sup> especially ectopic ventricular beats.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder <or the local representative of the marketing authorisation holder> using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## 8. Dosage for each species, routes and method of administration

Slow intravenous use.

These dosage instructions are given for guidance and must be adapted to the individual deficit and actual circulatory conditions.

Administer approximately 15 - 20 mg Ca<sup>2+</sup> (0.37 – 0.49 mmol Ca<sup>2+</sup>) and 10 – 13 mg Mg<sup>2+</sup> (0.41 - 0.53 mmol Mg<sup>2+</sup>) per kg bodyweight corresponding to approximately 1.0 - 1.4 ml of product per kg bodyweight.

If the animal's weight cannot be determined accurately, but has to be estimated, the following approach might be used:

Bottle size (ml)	Weight (kg)	Ca <sup>2+</sup> (mg/kg)	Mg <sup>2+</sup> (mg/kg)
500	350-475	15.1 – 20.4	10.5 – 14.3
750	500-725	14.8 – 21.5	10.3 – 15.0

After a minimum of 6 hours after treatment, a second treatment may be administered. The administration can be repeated twice at 24-hour intervals, if the hypocalcaemic condition is persisting.

## 9. Advice on correct administration

The intravenous infusion must be executed slowly over a period of 20-30 minutes.

## 10. Withdrawal periods

Meat and offal: Zero days  
Milk: Zero hours

## 11. Special storage precautions

Keep out of the sight and reach of children.

Do not refrigerate or freeze.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: use immediately.

## 12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste. Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

## 13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

## 14. MARKETING AUTHORISATION NUMBER AND PACK SIZES

Vm 36408/4003

Pack sizes: 500 ml and 750 ml.  
Not all pack sizes may be marketed.

## 15. PID LINK (Do not print heading)

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## 16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

Alfasan Nederland B.V.  
Kuipersweg 9  
3449 JA Woerden  
The Netherlands

Manufacturer responsible for batch release:

Bela-pharm GmbH & Co. KG  
Lohner Str. 19  
49377 Vechta  
Germany

## 17. Other information

POM-V

*Gavin Hall*

Approved: 03 February 2026

